Ignite Creation Date:
2024-05-06 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05258331
Status:
RECRUITING
Last Update Posted:
2022-03-18
First Post:
2022-02-14
Brief Title:
Clinical Trial to Evaluate the Safety Tolerability and Efficacy of CT303 in Patients With Psoriasis
Sponsor:
GC Cell Corporation
Organization:
GC Cell Corporation
Study Overview
Official Title:
An Open-label Dose-escalation Phase 1 Trial to Investigate the Safety Tolerability and Efficacy After Single- and Multiple-dose Administration of CT303 in Patients With Moderate to Severe Plaque Psoriasis
Status:
RECRUITING
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Investigate the Safety Tolerability Efficacy and pharmacodynamics properties of CT303 in patients with moderate to severe plaque psoriasis
Detailed Description:
This study is a multi-center open-label dose-escalation and dose-finding phase 1 clinical trial The primary purpose is to evaluate the safety and tolerability of CT303 and the secondary purpose is to evaluate the safety and efficacy of CT303 in patients with moderate to severe plaque psoriasis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None